Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07404306 · ClinicalTrials.gov registry record · Phase 1
Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users
A Phase 1 study, sponsored by Haisco-USA Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT07404306: Completed Phase 1 study, sponsored by Haisco-USA Pharmaceuticals.
NCT07404306 is a Phase 1 study that has completed, run by Haisco-USA Pharmaceuticals. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07404306, a Phase 1 study, has completed, sponsored by Haisco-USA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study. Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy nondependent, recreational CNS depressant drug users.
Primary Outcome
To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study
Interventions
- DRUG Placebo
- DRUG propofol
- DRUG HSK3486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-08-16 |
| Est. Completion | 2023-10-03 |
| Phase | Phase 1 |
What the finished NCT07404306 record still lists
NCT07404306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07404306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07404306 about?
NCT07404306 is a clinical study titled "Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users". Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study. Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy nondependent, recreational CNS depressant drug users.
What is the current status of trial NCT07404306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-08-16. Estimated completion is 2023-10-03.
What interventions are being tested in trial NCT07404306?
The interventions under investigation include: Placebo (DRUG), propofol (DRUG), HSK3486 (DRUG).
Who is sponsoring clinical trial NCT07404306?
This trial is sponsored by Haisco-USA Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07404306's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI